Sancuso + IV granisetron
Phase 1Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy Induced Nausea and Vomiting
Conditions
Chemotherapy Induced Nausea and Vomiting
Trial Timeline
— → —
NCT ID
NCT01596413About Sancuso + IV granisetron
Sancuso + IV granisetron is a phase 1 stage product being developed by Kyowa Kirin for Chemotherapy Induced Nausea and Vomiting. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01596413. Target conditions include Chemotherapy Induced Nausea and Vomiting.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy Induced Nausea and Vomiting were approved
Approved (3) Terminated (4) Active (14)
🔄recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01596426 | Phase 1 | Withdrawn |
| NCT01596413 | Phase 1 | Withdrawn |
Competing Products
20 competing products in Chemotherapy Induced Nausea and Vomiting